Navigation Links
BioCis Pharma Starts Phase IIa Trial in Psoriasis
Date:3/12/2009

TURKU, Finland, March 12 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.

"With the commencement of this clinical trial we expand our clinical activities to a new dermatological indication," says Lasse Leino, CEO of BioCis Pharma. "Together with the ongoing phase IIa clinical trial in patients with mild to moderate atopic dermatitis, this first study in psoriasis will quickly enable us to obtain data to support our full-scale phase II clinical development program of ProtoCure(TM) emulsion cream in chronic skin inflammation. We expect to get results from both studies by third quarter of 2009."

Psoriasis is an immune-mediated chronic inflammatory disease characterized by local lesions on the skin. It affects about 2 to 3 per cent of the general population in the Western countries. Psoriasis may significantly impair the life quality of the affected subjects, and it may lead to psoriatic arthritis, an inflammatory disease affecting the joints. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd is an innovative drug development company with a business idea to develop drug therapies based on a novel, patented therapeutic principle. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

http://www.biocis.com

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd. mobile phone +358-40-849-4694, lasse.leino@biocis.com.


'/>"/>
SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
7. Pharmaxis Appoints French Distributor for Aridol(TM)
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Linda, Ca (PRWEB) , ... April 24, 2017 ... ... protect proteins from thermal denaturation in a cellular milieu; however, the broad application ... a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, in ... to three startups through the UConn Innovation Fund. The $1.5 million UConn Innovation ... with UConn. , The UConn Innovation Fund provides investments of up to $100,000 ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology Center, Inc. ... technology-based businesses, recently earned a $77,518 grant from the Rural Maryland Council (RMC) ... FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is a public-private partnership ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the leading risk ... industries, is pleased to announce Holger Braemer as Vice President of its ... based in Germany. , Braemer is an integral part of USDM’s expansion of ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
Breaking Biology News(10 mins):